CD38‐Targeted Theranostics of Lymphoma with (89)Zr/(177)Lu‐Labeled Daratumumab

Lymphoma is a heterogeneous disease with varying clinical manifestations and outcomes. Many subtypes of lymphoma, such as Burkitt′s lymphoma and diffuse large B cell lymphoma, are highly aggressive with dismal prognosis even after conventional chemotherapy and radiotherapy. As such, exploring specif...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Lei, Li, Cuicui, Rosenkrans, Zachary T., Huo, Nan, Chen, Zhao, Ehlerding, Emily B., Huo, Yan, Ferreira, Carolina A., Barnhart, Todd E., Engle, Jonathan W., Wang, Rongfu, Jiang, Dawei, Xu, Xiaojie, Cai, Weibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Full Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132161/
https://www.ncbi.nlm.nih.gov/pubmed/34026426
http://dx.doi.org/10.1002/advs.202001879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132161/
https://www.ncbi.nlm.nih.gov/pubmed/34026426
http://dx.doi.org/10.1002/advs.202001879

Ejemplares similares